HRP20211243T1 - Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona - Google Patents
Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona Download PDFInfo
- Publication number
- HRP20211243T1 HRP20211243T1 HRP20211243TT HRP20211243T HRP20211243T1 HR P20211243 T1 HRP20211243 T1 HR P20211243T1 HR P20211243T T HRP20211243T T HR P20211243TT HR P20211243 T HRP20211243 T HR P20211243T HR P20211243 T1 HRP20211243 T1 HR P20211243T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- multiple myeloma
- cancer
- comprises administering
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 206010028980 Neoplasm Diseases 0.000 title claims 7
- 201000011510 cancer Diseases 0.000 title claims 7
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 25
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 10
- 208000034578 Multiple myelomas Diseases 0.000 claims 9
- 239000013543 active substance Substances 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- 229960003957 dexamethasone Drugs 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000011476 stem cell transplantation Methods 0.000 claims 2
- IXZOHGPZAQLIBH-NRFANRHFSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-NRFANRHFSA-N 0.000 claims 1
- VVHQVXXPZDALDV-BOXHHOBZSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione;hydrochloride Chemical compound Cl.O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 VVHQVXXPZDALDV-BOXHHOBZSA-N 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 150000003838 adenosines Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 231100000857 poor renal function Toxicity 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000009118 salvage therapy Methods 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Spoj za uporabu u metodi liječenja ili ovladavanja karcinomom kod pacijenta kojem je potrebno takvo liječenje ili ovladavanje, naznačen time što je spoj 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il) piperidin-2,6-dion sljedeće strukture:
[image]
ili njihov enantiomer ili smjesa enantiomera, ili njihova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, i
pri čemu je rak mijelom ili limfom.
2. Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je rak Hodgkinov limfom, ne-Hodgkinov limfom, kožni limfom T-stanica, kožni limfom B-stanica, difuzni limfom velikih B-stanica, folikularni limfom niskog stupnja, Waldenstromova makroglobulinemija, tinja mijelom ili indolentni mijelom.
3. Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je rak multipli mijelom.
4. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je rak relapsan ili refraktorni; proizvoljno pri čemu je rak otporan na lijekove.
5. Spoj za uporabu u skladu s patentnim zahtjevom 3, naznačen time što je multipli mijelom recidivan ili je refraktorrni multipli mijelom s oštećenom bubrežnom funkcijom.
6. Spoj za uporabu u skladu s patentnim zahtjevom 3, naznačen time što je multipli mijelom otporan na lijek na lenalidomid.
7. Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time što metoda obuhvaća davanje navedenog spoja pacijentima s multiplim mijelomom prije, za vrijeme ili nakon transplantacije autologne matične stanice periferne krvi; ili gdje metoda obuhvaća davanje navedenog spoja pacijentima s relapsom multiplog mijeloma nakon transplantacije matičnih stanica.
8. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što metoda nadalje obuhvaća davanje terapeutski učinkovite količine jedne ili više dodatnih aktivnih tvari, po želji je dodatno aktivno sredstvo odabrano iz skupine koju čine alkilirajuće sredstvo , analog adenozina, glukokortikoid, inhibitor kinaze, inhibitor SYK, inhibitor PDE3, inhibitor PDE7, doksorubicin, klorambucil, vinkristin, bendamustin, forskolin i rituksimab; po mogućnosti gdje je dodatno aktivno sredstvo rituksimab.
9. Spoj za uporabu prema zahtjevu 8, naznačen time, da je dodatno aktivno sredstvo deksametazon.
10. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačen time što metoda obuhvaća davanje navedenog spoja u kombinaciji s deksametazonom pacijentima s relapsom ili refraktornim multiplim mijelomom.
11. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačen time što metoda obuhvaća davanje navedenog spoja u kombinaciji s deksametazonom kao spasonosnu terapiju za pacijente s multiplim mijelomom nakon niskorizične transplantacije; ili gdje metoda obuhvaća davanje navedenog spoja u kombinaciji s deksametazonom kao terapiju održavanja pacijentima s multiplim mijelomom nakon transplantacije autologne koštane srži.
12. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što 3- (4 - ((4- (morfolinometil) benzil) oksi) -1-oksoizoindolin-2-il) piperidin-2,6-dion, ili enantiomer ili njihova smjesa enantiomera, ili njihova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, daje se u količini od oko 0,1 do oko 100 mg dnevno, po izboru u količini od oko 0.1 do oko 5 mg na dan ili u količini od oko 0.1, 0.2, 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 ili 100 mg dnevno, ili gdje se spoj daje oralno ili se daje u kapsuli ili tableti, po mogućnosti u 10 mg ili 25 mg kapsule.
13. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što se spoj daje 21 dan, nakon čega slijedi sedam dana odmora u 28-dnevnom ciklusu.
14. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je spoj (S) -3-(4- ((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion.
15. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je spoj (S)-3-(4-((4-(morfolinometil)benzil)oksi)-1 oksoizoindolin-2-il) piperidin-2,6-dion hidroklorid.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681447P | 2012-08-09 | 2012-08-09 | |
| US201261722727P | 2012-11-05 | 2012-11-05 | |
| PCT/US2013/054055 WO2014025960A1 (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| EP13751007.9A EP2882442B1 (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211243T1 true HRP20211243T1 (hr) | 2021-11-12 |
Family
ID=49004013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211243TT HRP20211243T1 (hr) | 2012-08-09 | 2021-08-03 | Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20140045843A1 (hr) |
| EP (2) | EP2882442B1 (hr) |
| JP (2) | JP6347782B2 (hr) |
| KR (3) | KR102414005B1 (hr) |
| CN (4) | CN114344307A (hr) |
| AU (1) | AU2013299627C1 (hr) |
| BR (1) | BR112015002285B1 (hr) |
| CA (1) | CA2881116C (hr) |
| CY (1) | CY1124622T1 (hr) |
| DK (1) | DK2882442T3 (hr) |
| EA (1) | EA029485B1 (hr) |
| ES (1) | ES2881220T3 (hr) |
| HK (1) | HK1211489A1 (hr) |
| HR (1) | HRP20211243T1 (hr) |
| HU (1) | HUE056127T2 (hr) |
| IL (3) | IL288506B2 (hr) |
| IN (1) | IN2015DN00886A (hr) |
| LT (1) | LT2882442T (hr) |
| MX (1) | MX367869B (hr) |
| NI (1) | NI201500012A (hr) |
| NZ (1) | NZ628078A (hr) |
| PH (1) | PH12015500212A1 (hr) |
| PL (1) | PL2882442T3 (hr) |
| PT (1) | PT2882442T (hr) |
| RS (1) | RS62201B1 (hr) |
| SG (3) | SG10202108516PA (hr) |
| SI (1) | SI2882442T1 (hr) |
| TW (2) | TWI653977B (hr) |
| UA (1) | UA116544C2 (hr) |
| WO (1) | WO2014025960A1 (hr) |
| ZA (1) | ZA201500564B (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| LT3202460T (lt) | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
| EP2691384B1 (en) | 2011-03-28 | 2016-10-26 | MEI Pharma, Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
| WO2014004990A2 (en) | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| BR112015005243A2 (pt) * | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| WO2016057503A1 (en) * | 2014-10-07 | 2016-04-14 | Celgene Corporation | Use of biomarkers for predicting clinical sensitivity to cancer treatment |
| MX2018003697A (es) * | 2015-09-25 | 2018-08-01 | Celgene Corp | Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos. |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| WO2018144445A1 (en) * | 2017-01-31 | 2018-08-09 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| US20210085663A1 (en) * | 2017-05-16 | 2021-03-25 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical braf mutations |
| KR20200009088A (ko) | 2017-05-23 | 2020-01-29 | 메이 파마, 아이엔씨. | 병용 요법 |
| PL3644999T3 (pl) * | 2017-06-30 | 2023-05-08 | Celgene Corporation | Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu |
| BR112020000442A2 (pt) | 2017-07-10 | 2020-07-21 | Celgene Corporation | compostos antiproliferativos e métodos de uso dos mesmos |
| CN111212643A (zh) | 2017-08-14 | 2020-05-29 | 梅制药公司 | 联合疗法 |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| US11709164B2 (en) | 2017-10-26 | 2023-07-25 | National University Of Singapore | Approach for universal monitoring of minimal residual disease in acute myeloid leukemia |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CN112839659A (zh) * | 2018-08-14 | 2021-05-25 | 梅制药公司 | 复发性滤泡性淋巴瘤的治疗 |
| JP7323603B2 (ja) * | 2018-09-07 | 2023-08-08 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式縮合フラン置換ピペリジンジオン系化合物 |
| WO2020072334A1 (en) | 2018-10-01 | 2020-04-09 | Celgene Corporation | Combination therapy for the treatment of cancer |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| JP2022554353A (ja) | 2019-11-07 | 2022-12-28 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用 |
| WO2021113212A1 (en) | 2019-12-02 | 2021-06-10 | Celgene Corporation | Therapy for the treatment of cancer |
| CA3162502A1 (en) | 2019-12-23 | 2021-07-01 | Yi Zhang | Smarca degraders and uses thereof |
| JP2023518423A (ja) | 2020-03-19 | 2023-05-01 | カイメラ セラピューティクス， インコーポレイテッド | Ｍｄｍ２分解剤およびそれらの使用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| MX2022015891A (es) * | 2020-06-25 | 2023-01-24 | Celgene Corp | Metodos para tratar cancer con terapias combinadas. |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| US8153659B2 (en) * | 2007-03-20 | 2012-04-10 | Celgene Corporation | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| LT3202460T (lt) * | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
| WO2011112933A1 (en) * | 2010-03-12 | 2011-09-15 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| AR085651A1 (es) * | 2011-03-11 | 2013-10-16 | Celgene Corp | Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona |
-
2013
- 2013-08-08 EP EP13751007.9A patent/EP2882442B1/en active Active
- 2013-08-08 CA CA2881116A patent/CA2881116C/en active Active
- 2013-08-08 EP EP21177385.8A patent/EP3949968A1/en active Pending
- 2013-08-08 SG SG10202108516PA patent/SG10202108516PA/en unknown
- 2013-08-08 UA UAA201501971A patent/UA116544C2/uk unknown
- 2013-08-08 RS RS20210904A patent/RS62201B1/sr unknown
- 2013-08-08 PL PL13751007T patent/PL2882442T3/pl unknown
- 2013-08-08 NZ NZ628078A patent/NZ628078A/en unknown
- 2013-08-08 CN CN202110938460.9A patent/CN114344307A/zh active Pending
- 2013-08-08 PT PT137510079T patent/PT2882442T/pt unknown
- 2013-08-08 SG SG10201701057SA patent/SG10201701057SA/en unknown
- 2013-08-08 TW TW102128576A patent/TWI653977B/zh active
- 2013-08-08 KR KR1020217018115A patent/KR102414005B1/ko active IP Right Grant
- 2013-08-08 LT LTEPPCT/US2013/054055T patent/LT2882442T/lt unknown
- 2013-08-08 SG SG11201500998QA patent/SG11201500998QA/en unknown
- 2013-08-08 CN CN201380052496.0A patent/CN104837491A/zh active Pending
- 2013-08-08 DK DK13751007.9T patent/DK2882442T3/da active
- 2013-08-08 IN IN886DEN2015 patent/IN2015DN00886A/en unknown
- 2013-08-08 HU HUE13751007A patent/HUE056127T2/hu unknown
- 2013-08-08 IL IL288506A patent/IL288506B2/en unknown
- 2013-08-08 CN CN201711401933.1A patent/CN108245518B/zh active Active
- 2013-08-08 WO PCT/US2013/054055 patent/WO2014025960A1/en active Application Filing
- 2013-08-08 BR BR112015002285-5A patent/BR112015002285B1/pt active IP Right Grant
- 2013-08-08 AU AU2013299627A patent/AU2013299627C1/en active Active
- 2013-08-08 US US13/962,776 patent/US20140045843A1/en not_active Abandoned
- 2013-08-08 TW TW107117959A patent/TWI723266B/zh active
- 2013-08-08 ES ES13751007T patent/ES2881220T3/es active Active
- 2013-08-08 MX MX2015001775A patent/MX367869B/es active IP Right Grant
- 2013-08-08 EA EA201590345A patent/EA029485B1/ru not_active IP Right Cessation
- 2013-08-08 SI SI201331908T patent/SI2882442T1/sl unknown
- 2013-08-08 KR KR1020157006019A patent/KR102146848B1/ko active Application Filing
- 2013-08-08 CN CN202110936758.6A patent/CN114366746A/zh active Pending
- 2013-08-08 KR KR1020207023283A patent/KR102266510B1/ko active IP Right Grant
- 2013-08-08 JP JP2015526690A patent/JP6347782B2/ja active Active
-
2015
- 2015-01-26 ZA ZA2015/00564A patent/ZA201500564B/en unknown
- 2015-01-29 IL IL237013A patent/IL237013B/en active IP Right Grant
- 2015-01-30 PH PH12015500212A patent/PH12015500212A1/en unknown
- 2015-02-06 NI NI201500012A patent/NI201500012A/es unknown
- 2015-12-17 HK HK15112438.8A patent/HK1211489A1/xx unknown
-
2016
- 2016-05-13 US US15/154,838 patent/US20160256468A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017168A patent/JP2018100276A/ja not_active Withdrawn
-
2019
- 2019-08-01 US US16/529,233 patent/US20190388429A1/en active Pending
-
2020
- 2020-07-27 IL IL276319A patent/IL276319B/en unknown
-
2021
- 2021-07-16 CY CY20211100645T patent/CY1124622T1/el unknown
- 2021-08-03 HR HRP20211243TT patent/HRP20211243T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211243T1 (hr) | Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona | |
| AU2020201321B2 (en) | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| US8557847B2 (en) | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | |
| NZ708563A (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| KR20210095118A (ko) | Cxcr4 억제제의 조성물 및 제조 방법 및 용도 | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| US20090149511A1 (en) | Administration of an Inhibitor of HDAC and an mTOR Inhibitor | |
| CA2725390C (en) | Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer | |
| KR20130045341A (ko) | 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여 | |
| CA2601509A1 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| JP2010509370A (ja) | 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ | |
| WO2009126537A1 (en) | Administration of an inhibitor of hdac and an hmt inhibitor | |
| JP2009507081A (ja) | ＨＤａｃ阻害による神経発生の調整 | |
| JP2017525713A5 (hr) | ||
| JP6419294B2 (ja) | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 | |
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos | |
| EP3698790A1 (en) | Methods and compositions for treating abnormal cell growth | |
| WO2018091999A1 (en) | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer | |
| BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| MX2011011058A (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| MX2014010538A (es) | Formas cristalinas de cloruro de hidrógeno de 1- (3-ter-butil-1-p-tolil-1h-pirazol-5-il)-3- (5-fluoro-2- (1- (2- hidroxietil) -1h-indazol-5-iloxi) bencil) urea.. | |
| US20130137697A1 (en) | Compositions, methods of use, and methods of treatment | |
| AU2010257456A1 (en) | 5 HT receptor mediated neurogensis | |
| CA2726300A1 (en) | 5 ht receptor mediated neurogenesis |